Topic

All

13
Sep
2017

The Long Run, Ep. 1: Conversation with Alnylam CEO John Maraganore

Podcast listeners, check it out: Today, I’m starting a new podcast for biotech adventurers like you – executives, investors, scientists. It’s called The Long Run. Here’s the gist: Antarctic explorer Ernest Shackleton, if he were alive, would appreciate biotech. Today’s scientific entrepreneurs must be ready for the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return...
Read More
17
Aug
2017

We Can Follow Through On Our Own After Charlottesville

[Editor’s Note: Steve Graham of Fenwick & West is one of biotech’s leading corporate attorneys. His book, “Invisible Ink: Navigating racism in corporate America” was published in April.] I spent my first few years of elementary school in segregated schools.  Beaches were segregated.  The drinking fountains and restrooms were labeled.  At movie theatres, colored people were directed to the balcony.  At...
Read More
16
Aug
2017

At What Price a Seat at the Table?

[Editor’s Note: This editorial was co-authored by Steve Holtzman, CEO of Decibel Therapeutics, and Jeremy Levin, CEO of Ovid Therapeutics in the aftermath of violent clashes between white supremacists and counter-protesters in Charlottesville, Virginia.] FACT 1: The overwhelming majority of the men and women in the biopharmaceutical industry, scientists and non-scientists alike, have been drawn to their profession by the noble...
Read More